Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

2.1%

18 terminated/withdrawn out of 868 trials

Success Rate

91.7%

+5.1% vs industry average

Late-Stage Pipeline

10%

84 trials in Phase 3/4

Results Transparency

3%

6 of 199 completed trials have results

Key Signals

217 recruiting6 with results6 terminated12 withdrawn

Enrollment Performance

Analytics

N/A
255(43.2%)
Phase 2
137(23.2%)
Phase 1
106(18.0%)
Phase 3
48(8.1%)
Phase 4
36(6.1%)
Early Phase 1
8(1.4%)
590Total
N/A(255)
Phase 2(137)
Phase 1(106)
Phase 3(48)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (868)

Showing 20 of 868 trials
NCT07856355Phase 4Not Yet Recruiting

Tobramycin Nebulization to Prevent Multidrug-Resistant Ventilator-Associated Pneumonia

Role: collaborator

NCT07410715Recruiting

Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma

Role: lead

NCT07855965Phase 2Recruiting

Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer

Role: lead

NCT06627712Phase 3Recruiting

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Role: lead

NCT07715279Phase 2Recruiting

Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression

Role: lead

NCT07131644Phase 2Recruiting

Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma

Role: lead

NCT06737913Phase 2Recruiting

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Role: collaborator

NCT07835737Phase 1Not Yet Recruiting

Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma

Role: lead

NCT07718126Phase 4Recruiting

Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)

Role: lead

NCT07565740Phase 1Recruiting

Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC

Role: lead

NCT07562841Phase 1Recruiting

Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy

Role: lead

NCT06798363Phase 2Recruiting

Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma

Role: lead

NCT07830147Completed

HAIC Rechallenge in Biliary Tract Cancer and Colorectal Cancer Liver Metastases: Efficacy and Safety in Patients Resistant to Previous Systemic Chemotherapy

Role: lead

NCT07744659Not ApplicableRecruiting

Spinal Cord Stimulation for Poststroke Spasticity

Role: collaborator

NCT07572864Phase 2Recruiting

Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC

Role: lead

NCT07823543Not ApplicableNot Yet Recruiting

Educational Videos for Thyroid Surgery Patient

Role: lead

NCT07809776Not ApplicableRecruiting

Tai Chi for Cancer-Related Fatigue During Radiotherapy in Patients With Head and Neck Cancer

Role: lead

NCT05339529Not ApplicableCompleted

Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

Role: collaborator

NCT07381075Phase 2Recruiting

A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Role: lead

NCT06358209Not ApplicableRecruiting

Safety and Efficacy of Ventricular Irrigation for Ventriculitis

Role: collaborator